ATE252095T1 - Palladium katalysierter ringschluss von triazolyl-tryptamin - Google Patents

Palladium katalysierter ringschluss von triazolyl-tryptamin

Info

Publication number
ATE252095T1
ATE252095T1 AT95918939T AT95918939T ATE252095T1 AT E252095 T1 ATE252095 T1 AT E252095T1 AT 95918939 T AT95918939 T AT 95918939T AT 95918939 T AT95918939 T AT 95918939T AT E252095 T1 ATE252095 T1 AT E252095T1
Authority
AT
Austria
Prior art keywords
tryptamine
triazolyl
ring closure
catalyzed ring
palladium catalyzed
Prior art date
Application number
AT95918939T
Other languages
German (de)
English (en)
Inventor
Cheng Y Chen
Robert D Larsen
Thomas R Verhoeven
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE252095T1 publication Critical patent/ATE252095T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Inorganic Insulating Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AT95918939T 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin ATE252095T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
PCT/US1995/005506 WO1995032197A1 (en) 1994-05-24 1995-05-19 Palladium catalyzed ring closure of triazolyl tryptamine

Publications (1)

Publication Number Publication Date
ATE252095T1 true ATE252095T1 (de) 2003-11-15

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918939T ATE252095T1 (de) 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin

Country Status (24)

Country Link
US (1) US5567824A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0763032B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3947216B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100385027B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1157390C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE252095T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU688505B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69531939T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0763032T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2207648T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI116899B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1041262B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP950304B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9605838A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ285539A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT763032E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO118586B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2138496C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK284495B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA52586C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995032197A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49345B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6542896A (en) * 1995-07-11 1997-02-10 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
WO1998006725A1 (en) * 1996-08-13 1998-02-19 Merck & Co., Inc. Palladium catalyzed indolization
HK1045998B (zh) * 1999-06-28 2005-06-03 詹森药业有限公司 呼吸道合胞病毒复制抑制剂
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
CA2552663A1 (en) * 2004-01-09 2005-07-28 Ratiopharm Gmbh Crystalline forms of rizatriptan benzoate
ES2340861T3 (es) * 2004-01-28 2010-06-10 Ratiopharm Gmbh Procedimientos de sintesis e intermedios para la fabricacion de rizatriptan.
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
US20090062550A1 (en) * 2005-11-14 2009-03-05 Matrix Laboratories Ltd Process for the Large Scale Production of Rizatriptan Benzoate
EP1981860B1 (en) * 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
BR112018015367A2 (pt) 2016-01-27 2018-12-18 Instar Tech A S carreadores oromucosais de nanofibra para tratamento terapêutico

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
AU2467195A (en) 1995-12-18
TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-03-11
DE69531939T2 (de) 2004-07-29
CN1322725A (zh) 2001-11-21
KR100385027B1 (ko) 2003-08-14
DE69531939D1 (de) 2003-11-20
HU226460B1 (en) 2008-12-29
AU688505B2 (en) 1998-03-12
HK1009045A1 (en) 1999-05-21
DK0763032T3 (da) 2004-02-09
SK149896A3 (en) 1997-09-10
CN1157390C (zh) 2004-07-14
JP3947216B2 (ja) 2007-07-18
PT763032E (pt) 2004-02-27
KR970703336A (ko) 1997-07-03
FI964669L (fi) 1996-11-22
FI964669A0 (fi) 1996-11-22
HK1041262B (zh) 2005-04-15
MX9605838A (es) 1997-12-31
HUT76469A (en) 1997-09-29
CN1077104C (zh) 2002-01-02
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
YU49345B (sh) 2005-07-19
US5567824A (en) 1996-10-22
EP0763032B1 (en) 2003-10-15
YU33495A (sh) 1998-07-10
EP0763032A1 (en) 1997-03-19
ES2207648T3 (es) 2004-06-01
RO118586B1 (ro) 2003-07-30
NZ285539A (en) 1998-06-26
HRP950304B1 (en) 2004-12-31
FI116899B (fi) 2006-03-31
JPH10500680A (ja) 1998-01-20
HK1041262A1 (en) 2002-07-05
CN1152920A (zh) 1997-06-25
HRP950304A2 (en) 1997-08-31
HU9603236D0 (en) 1997-01-28
WO1995032197A1 (en) 1995-11-30
SK284495B6 (sk) 2005-05-05

Similar Documents

Publication Publication Date Title
ATE252095T1 (de) Palladium katalysierter ringschluss von triazolyl-tryptamin
DE69413542D1 (de) Perhydroisoindolderivate als substanz p antagonisten
EA200000393A1 (ru) Химические соединения
ATE284853T1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
DE60027420D1 (de) Tri-aryl-säurederivate als ppar rezeptor liganden
FI932012A0 (fi) Foerfarande foer framstaellning av arylpiperazinyl-heterocykliska foereningar
NO873568L (no) Alfa-alkyl-4-amino-kinolinmetanoler og 1-(4-aralkylamino-3-kinolinyl)alkanoler, samt fremgangsmaate for fremstilling derav.
DK129282A (da) Fremgangsmaade til fremstilling af indolylethylderivater
ATE275545T1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
TR200201684T2 (tr) Fenilpiperazinil türevleri
NO963117L (no) Indol-derivater som 5-HT1-agonister
ATE48835T1 (de) Chinolylglycinamidderivate, verfahren zu ihrer herstellung und therapeutische verwendung als psychotrope.
YU217181A (en) Process for preparing 2-(1,4-benzodioxane-2-ylalkyl)-imidazoles
ATE221872T1 (de) Herstellung von tri-iodo-benzol-verbindungen
CA2190851A1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
DE69906243D1 (de) 2-Indanmethanolderivate und ihre Verwendung als Riechstoffe
Takahashi et al. The Synthesis of 1, 3, 4-Benzotriazepin-5-one Derivatives from Isatoic Anhydrides
DK501480A (da) Fremgangsmaade til fremstilling af substituerede 2-phenylamino-imidazoliner-(2).
BR9705662A (pt) Piridinas substituìdas.
KR970042548A (ko) 이미다조 피리딘 유도체,이의 제조방법 및 이를 함유한 약제학적 조성물
DK0614890T3 (da) Fremgangsmåde til fremstilling af eventuelt 2-substituerede 5-chlorimidazoler.
HUP9701476A2 (hu) Eljárás dexfenfluramin-hidroklorid előállítására és intermedierjeik
BR8203989A (pt) Processo para a preparacao de hidrazidinas
GB9815481D0 (en) Pharmaceuticals
DK0557519T3 (da) Fremgangsmåde til fremstilling af sulfonamidderivater af norbornan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0763032

Country of ref document: EP

EEFA Change of the company name